Authors

Julie Graff, MD, Oregon Health

Julie Gralow, MD

Latest:

Dr. Gralow on Future Challenges in Cancer Care in the Post–COVID-19 Era

Julie R. Gralow, MD, discusses future challenges in cancer care following the COVID-19 pandemic.

Julie Grisham

Latest:

Combining Chemo With mTOR Inhibitors Shows Promise in pNETS

Combining the chemotherapy streptozotocin with drugs that target the mTOR pathway may be an effective way to treat pancreatic neuroendocrine tumors.

Julie M. Vose, MD

Latest:

Dr Vose on the Investigation of Epcoritamab in Relapsed/Refractory Follicular Lymphoma

Julie M. Vose, MD, MBA, discusses the investigation of epcoritamab in relapsed/refractory follicular lymphoma.

Julie N. Graff, MD

Latest:

Dr. Graff on Combination Regimens With Checkpoint Inhibitors in mCRPC

Julie N. Graff, MD, discusses potential combination regimens with checkpoint inhibitors in metastatic castration-resistant prostate cancer.

Julie R. Brahmer, MD

Latest:

Clinical Pearls and Closing Thoughts on NSCLC Treatment Landscape

Closing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.

Julie R. Gralow, MD

Latest:

Dr. Gralow on the Integration on Precision Medicine Into Oncology

Julie R. Gralow, MD, discusses the integration of precision medicine into oncology.

Julie R. Nangia

Latest:

Dr. Nangia on Challenges Facing Hair Loss Treatment for Breast Cancer

Julie R. Nangia, MD, assistant professor, Breast Center-Clinic, faculty senator, Baylor College of Medicine, discusses hair loss prevention treatment for patients with breast cancer.

Julie R. Nangia, MD

Latest:

Dr. Nangia Discusses the Logistics of Implementing a Scalp Cooling System

Julie R. Nangia, MD, assistant professor of medicine, Baylor College of Medicine, discusses some logistical factors that oncologists and health care providers should know regarding implementing a scalp cooling system.

Julie Rani Nangia, MD

Latest:

Baylor Team Helps Establish Scalp-Cooling Benefits for Breast Cancer Patients

Supported by research, there have been recent developments in using scalp cooling to combat chemotherapy-induced alopecia for patients with breast cancer.

Julie Song, MPH, CPHRM, Patient Safety Risk Manager, The Doctors Company

Latest:

Should Physicians Friend or Unfriend Social Media? 'It's Complicated'

Compared to other industries, the medical profession has been late in recognizing the many benefits of social media. In the past few years, it has entered into an uneasy relationship with the new medium.

Julien Taieb, MD, PhD

Latest:

Dr Taieb on the FDA Approval of TAS-102 Plus Bevacizumab in mCRC

Juliet N. Barker, MBSS

Latest:

Dr. Barker on Cord Blood Transplantation

Juliet N. Barker, MBSS, director, Cord Blood Transplantation Program, Memorial Sloan-Kettering Cancer Center, discusses using double-unit cord blood transplantation with a haplo-identical donor in patients with hematologic malignancies.

Julio Chavez, MD

Latest:

Dr. Chavez on Blinatumomab in ALL

Julio Chavez, MD, assistant member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of blinatumomab (Blincyto) in patients with acute lymphoblastic leukemia (ALL).

Julio Chavez, MD et al

Latest:

Biology and Management of Diffuse Large B-cell Lymphoma

Recent statistics show lymphoid malignancies to be the fifth most common cause of cancer-related death in the United States.

Julio Chavez, MD, Moffitt Cancer Center

Latest:

A New Chapter in DLBCL: Uncovering New Treatment Options For Your Patients

Julio M. Pow-Sang, MD

Latest:

Epigenetic Variations in Prostate Tumors May Determine Choice Between Definitive Treatment and Active Surveillance

Prostate cancer is the most common cancer and second leading cause of cancer mortality in American men. Nevertheless, it is estimated that only 3% of the patients will die because of their cancer, while the majority will die of competing causes.

Julio Pow-Sang, MD

Latest:

Dr. Julio Pow-Sang on Options for Low-and Intermediate-Risk Prostate Cancer

Jun Gong, MD

Latest:

Dr Gong on the Benefits and Limitations of PARP Inhibitor–Based Regimens in mCRPC

Jun Gong, MD, discusses the benefits and limitations of PARP inhibitor–based regimens in metastatic castration-resistant prostate cancer.

Juneko Grilley-Olson, MD

Latest:

Dr. Grilley-Olson on Treating Patients Based on Molecular Profile

Juneko Grilley-Olson, MD, assistant professor, UNC-Chapel Hill, Clinical Research, Thoracic Oncology Program, Head and Neck Oncology Program, Bone and Soft Tissue Oncology Program, UNC Lineberger Comprehensive Cancer Center, discusses treating patients with cancer based on their molecular profile.